Tessera
Folgen

The ASAP Discovery Consortium

@asapdiscovery.bsky.social

ASAP uses artificial intelligence and computational chemistry to accelerate structure-based open science antiviral drug discovery and deliver oral antivirals for pandemics with the goal of global, equitable, and affordable access.

35 Posts292 Follower12 Folgt
The ASAP Discovery Consortium@asapdiscovery.bsky.social · 11mo ago

Read about the scientists on the front lines working tirelessly to make antivirals to prevent future pandemics in the Kris White lab at Mount Sinai: health.mountsinai.org/blog/stories...

Stories Behind the Science: Preparing to Fight the Next Epidemic | Mount Sinai Today

Antivirals saved many lives during the COVID-19 pandemic, and Mount Sinai researchers are involved in discovering new treatments as part a preparedness initiative spearheaded by the National Institute...

health.mountsinai.org

The ASAP Discovery Consortium@asapdiscovery.bsky.social · last yr.

Join us for the Wed 18 Jun Antiviral Drug Discovery Open Science Forum at 11A ET to hear from Ingrid de Visser-Kamerling and Jeroen Kruter of INFECTA on Controlled Human Infection Models, as well as Annette von Delft and Peter Sjö of ASAP on the discovery of DNDi-6510! asapdiscovery.org/forum/

Antiviral Drug Discovery (AViDD) Open Science Forum

A public venue to enable NIH-funded AViDD Centers to openly exchange and disseminate information in a pre-competitive fashion.

asapdiscovery.org

The ASAP Discovery Consortium@asapdiscovery.bsky.social · last yr.

Join today's Antiviral Drug Discovery Open Science Forum at 11A ET to hear Warren Thompson (‪ASAP @diamondlightsource.bsky.social‬) discuss robotic fragment progression and Juan Carlos de la Torre (‪CAMPP @scripps.edu‬) present strategies to combat human mammarenaviruses: asapdiscovery.org/forum/

Antiviral Drug Discovery (AViDD) Open Science Forum

A public venue to enable NIH-funded AViDD Centers to openly exchange and disseminate information in a pre-competitive fashion.

asapdiscovery.org

The ASAP Discovery Consortium@asapdiscovery.bsky.social · last yr.

ASAP is incredibly proud to help pioneer new ways of making medicines globally affordable and accessible for all.

Drugs for Neglected Diseases initiative (DNDi)@dndi.org · last yr.

Did you know that we can manage patents in a way that serves the public good? Our Intellectual Property & Access Leader shares why, together with our partners from the @asapdiscovery.bsky.social, we are filing a #patent for a promising new #molecule that we developed together. shorturl.at/IgL80

The ASAP Discovery Consortium@asapdiscovery.bsky.social · last yr.

ASAP, OpenADMET (@openadmet.bsky.social), and Polaris Hub (@polarishub.io) are hosting a virtual meeting on Wed 30 Apr to learn from top performers in our recently concluded blind modeling challenge. To join or learn more about these efforts, check out: www.linkedin.com/feed/update/...

ASAP:OpenADMET:Polaris Blind Challenge Participant Showcase | Hugo MacDermott-Opeskin

ASAPDiscovery, Polaris - Benchmarks for methods that matter and OpenADMET  are hosting a session for some of the top performers from our recently concluded blind challenge to showcase their methods! ...

linkedin.com

The ASAP Discovery Consortium@asapdiscovery.bsky.social · last yr.

This Wed 16 Apr at 11.00A ET, the Antiviral Drug Discovery Open Science Forum features talks on Dengue antiviral discovery and development from Xuping Xie (@utmbhealth.bsky.social) and Darlene Chen (@novartis.bsky.social) of the UNAPP AViDD! asapdiscovery.org/forum

Antiviral Drug Discovery (AViDD) Open Science Forum

A public venue to enable NIH-funded AViDD Centers to openly exchange and disseminate information in a pre-competitive fashion.

asapdiscovery.org

Ed Griffen@griffen-ed.bsky.social · last yr.

Massive credit to all members of @asapdiscovery.bsky.social :- drug discovery is a massive team sport. Especially the chemists at Enamine working through the war.

C&EN (Chemical & Engineering News)@cenmag.bsky.social · last yr.

At #ACSSpring2025, Ed Griffen of MedChemica disclosed the structure of a pancoronavirus antiviral that targets the main protease of the two different coronaviruses that cause Middle East respiratory syndrome (MERS) and COVID-19. cen.acs.org/acs-news/acs... 🧪

The ASAP Discovery Consortium@asapdiscovery.bsky.social · last yr.

ASAP lead med chemist Ed Griffen (@griffen-ed.bsky.social) and @dndi.org Access Leader Pascale Boulet explain how ASAP is using patents to serve the common good by enabling globally equitable and affordable access to medicines in this feature in @cenmag.bsky.social: cen.acs.org/pharmaceutic...

Opinion: How patents can serve the common good

We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that

cen.acs.org

The ASAP Discovery Consortium@asapdiscovery.bsky.social · last yr.

Exciting news! The structure of the new MERS-CoV/SARS-CoV-2 oral antiviral developed by the ASAP Discovery consortium has been disclosed today. Read this thread for all the details:

Drugs for Neglected Diseases initiative (DNDi)@dndi.org · last yr.

📢Important announcement! Today, the @asapdiscovery.bsky.social consortium disclosed the structure of our preclinical candidate, ASAP-0017445, a promising broad-spectrum antiviral with potent activity against SARS-CoV2 and other viruses belonging to the same family. (1/10)

The ASAP Discovery Consortium@asapdiscovery.bsky.social · last yr.

If you're attending the American Chemical Society (ACS) meeting either physically or virtually, tune in to today's talk disclosing ASAP's new oral antiviral candidate aiming to help protect against future pandemics.

The ASAP Discovery Consortium@asapdiscovery.bsky.social · last yr.

Lead medicinal chemist Ed Griffen (@griffen-ed.bsky.social) will be disclosing the new ASAP MERS-CoV/SARS-CoV-2 oral antiviral at @acs.org on Tue 25 Mar! Tune in to this virtual session to hear about its discovery and development! acs.digitellinc.com/live/34/sess...

ACS talk 4181593 - Discovery of non-peptidomimetic oral combined MERS and SARS-CoV-2 anti-virals Presented by Ed Griffen Part of the session "Developing Countermeasures for Viruses of Pandemic Potential" Room: Digital Session (Digital Meeting) Overview: The COVID-19 pandemic was a stark reminder that a barren global antiviral pipeline has grave humanitarian consequences. Pandemics could be prevented, in principle, by accessible, easily deployable broad-spectrum oral antivirals. Here we report the discovery of a family non-peptidomimetic spirolactams that target critical pathogenic coronaviridae including SARS-CoV-2 and MERS-CoV. As part of the ASAP AViDD centre(www.asapdiscovery.org) we expanded the work of the COVID Moonshot's drug discovery campaign targeting the SARS-CoV-2 main protease to deliver orally active compounds with promising in vivo profiles. Using a combination of active learning based medicinal chemistry, alchemical free energy calculations and structure-based design we were able to extend the coronavirus spectrum and optimise the ADMET properties of the series leading to the first public disclosure of the preclinical candidate.
The ASAP Discovery Consortium@asapdiscovery.bsky.social · last yr.

Three days to go until the unveiling of our MERS-CoV/SARS-CoV-2 oral antiviral candidate for preclinical development!

The ASAP Discovery Consortium@asapdiscovery.bsky.social · last yr.

Lead medicinal chemist Ed Griffen (@griffen-ed.bsky.social) will be disclosing the new ASAP MERS-CoV/SARS-CoV-2 oral antiviral at @acs.org on Tue 25 Mar! Tune in to this virtual session to hear about its discovery and development! acs.digitellinc.com/live/34/sess...

ACS talk 4181593 - Discovery of non-peptidomimetic oral combined MERS and SARS-CoV-2 anti-virals Presented by Ed Griffen Part of the session "Developing Countermeasures for Viruses of Pandemic Potential" Room: Digital Session (Digital Meeting) Overview: The COVID-19 pandemic was a stark reminder that a barren global antiviral pipeline has grave humanitarian consequences. Pandemics could be prevented, in principle, by accessible, easily deployable broad-spectrum oral antivirals. Here we report the discovery of a family non-peptidomimetic spirolactams that target critical pathogenic coronaviridae including SARS-CoV-2 and MERS-CoV. As part of the ASAP AViDD centre(www.asapdiscovery.org) we expanded the work of the COVID Moonshot's drug discovery campaign targeting the SARS-CoV-2 main protease to deliver orally active compounds with promising in vivo profiles. Using a combination of active learning based medicinal chemistry, alchemical free energy calculations and structure-based design we were able to extend the coronavirus spectrum and optimise the ADMET properties of the series leading to the first public disclosure of the preclinical candidate.
Cole Group@colegroupncl.bsky.social · 2y ago

Our team is having fun trying out the binding pose challenge! Check it out below, the organisers have done a great job making the data easy to access and understand!

The ASAP Discovery Consortium@asapdiscovery.bsky.social · 2y ago

Working on predictive models for drug discovery? Here's your chance to see how well your models actually work! Together with @polarishub.io and OpenADMET, we've launched a blind prospective challenge to see how well predictive models for drug discovery can actually predict real drug discovery data!